Cover Image
市場調查報告書

核受體ROR伽馬:開發中產品分析

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 379066
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
核受體ROR伽馬:開發中產品分析 Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 98 Pages
簡介

本報告提供以核受體ROR伽馬為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

核受體ROR伽馬 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Aurigene Discovery Technologies Limited
  • Beijing Hanmi Pharmaceutical Co., Ltd.
  • Biogen Inc
  • Brickell Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • 日本煙草產業
  • Lead Pharma Holding B.V.
  • Nuevolution AB
  • Pfizer Inc.
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals, Inc.
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • Visionary Pharmaceuticals, Inc.
  • Vitae Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1009TDB

Summary:

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Receptor ROR Gamma - Pipeline Review, H2 2017, outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (RORγ) is a protein encoded by the RORC gene. RORγ is member of the nuclear receptor family of transcription factors. It exist in two isoforms RORγ and RORγt. RORγ is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R ORγt, appears to be highly restricted to the thymus. RORγ isoform is involved in the regulation of circadian rhythms and RORγt plays an important regulatory role in thymopoiesis and in inhibiting apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 20, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology, Metabolic Disorders and Other Diseases which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Asthma, Axial Spondyloarthritis, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Metastatic Cancer, Neuromyelitis Optica (Devic's Syndrome), Orphan Diseases, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
    • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advinus Therapeutics Ltd
    • Allergan Plc
    • Arrien Pharmaceuticals LLC
    • AstraZeneca Plc
    • Aurigene Discovery Technologies Ltd
    • Beijing Hanmi Pharmaceutical Co Ltd
    • Biogen Inc
    • Brickell Biotech Inc
    • Bristol-Myers Squibb Company
    • Celgene Corp
    • Eli Lilly and Company
    • Genentech Inc
    • Genfit SA
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Lead Pharma Holding BV
    • Lycera Corp
    • Maruho Co Ltd
    • Nuevolution AB
    • Orphagen Pharmaceuticals Inc
    • Pfizer Inc
    • Phenex Pharmaceuticals AG
    • Reata Pharmaceuticals Inc
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
    • ABBV-553 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARN-6039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-0284 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-6000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRC-39815 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2981278 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMU-366 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-71 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-3534 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTE-451 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LYC-55716 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LYC-56056 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis and Psoriatic Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RORC for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-2211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TGFTX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMP-778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPR-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTP-43742 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTP-45489 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 10, 2017: Phenex announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I
      • Jan 04, 2017: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors
      • Nov 04, 2016: Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists
      • Sep 26, 2016: GENFIT: Successful identification of RORt inverse agonists as candidates for regulatory pre-IND studies
      • Aug 01, 2016: Arrien Pharmaceuticals Provides Update on ARN-6039
      • Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
      • Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis
      • May 16, 2016: Arrien Pharmaceuticals Initiates Phase I Clinical trials of ARN-6039
      • May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug
      • Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039
      • Apr 19, 2016: Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research Annual Meeting
      • Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
      • Dec 17, 2015: Phenex reaches milestone in collaboration with Janssen
      • Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
      • Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1)
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AbbVie Inc, H2 2017
  • Pipeline by Advinus Therapeutics Ltd, H2 2017
  • Pipeline by Allergan Plc, H2 2017
  • Pipeline by Arrien Pharmaceuticals LLC, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
  • Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Biogen Inc, H2 2017
  • Pipeline by Brickell Biotech Inc, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by Eli Lilly and Company, H2 2017
  • Pipeline by Genentech Inc, H2 2017
  • Pipeline by Genfit SA, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Pipeline by Lead Pharma Holding BV, H2 2017
  • Pipeline by Lycera Corp, H2 2017
  • Pipeline by Maruho Co Ltd, H2 2017
  • Pipeline by Nuevolution AB, H2 2017
  • Pipeline by Orphagen Pharmaceuticals Inc, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Phenex Pharmaceuticals AG, H2 2017
  • Pipeline by Reata Pharmaceuticals Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top